Categories: Health

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 | Source: ZENTALIS PHARMACEUTICALS

SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on October 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted the following equity awards: non-qualified stock options to purchase an aggregate of 400,000 shares of the Company’s common stock to James B. Bucher, JD, who joined the Company as Chief Legal Officer and Corporate Secretary, and non-qualified stock options to purchase an aggregate of 15,000 shares of the Company’s common stock to two (2) additional newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $1.54 per share, which is equal to the closing price of Zentalis’ common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.

Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.

About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Contacts:
Aron Feingold – VP, IR & Corp Comms
ir@zentalis.com

GlobeNews Wire

Recent Posts

LAS VEGAS TO WELCOME DIRECT, NONSTOP SERVICE FROM PARIS ON AIR FRANCE BEGINNING APRIL 15, 2026

Seasonal service to run through October 24, 2026Tickets on sale now at AirFrance.us LAS VEGAS…

14 minutes ago

ROYAL CARIBBEAN REVEALS SUMMER 2027 ADVENTURES TO ALASKA

Vacationers are in for an action-packed lineup from Anthem of the Seas and its first-ever…

15 minutes ago

Alps Blockchain Announces Corporate Rebranding to Alps

Reflecting its evolution into a global builder of next-generation data center infrastructure powering Bitcoin and, in…

16 minutes ago

NYSE Content Advisory: Pre-Market Update + Uniphore raises $260 million to boost AI leadership

NEW YORK, Oct. 22, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a…

16 minutes ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a…

1 hour ago

BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the…

1 hour ago